Details of the Drug

General Information of Drug (ID: DMWF5R4)

Drug Name
Melphalan flufenamide
Synonyms J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [1]
Ovarian cancer 2C73 Phase 1/2 [2]
Plasma cell myeloma 2A83.1 Phase 1/2 [3]
ATC Code
L01AA10: Melphalan flufenamide
L01AA: Nitrogen mustard analogues
L01A: ALKYLATING AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 498.4
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 14
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 3143 mgh/L [4]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 432 mcg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4-15 min [4]
Clearance
The clearance of drug is 692 L/h [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.1 minutes (melphalan flufenamide), and 70 minutes (melphalan) [5]
Metabolism
The drug is metabolized to desethyl-melphalan and melphalan [5]
Vd
The volume of distribution (Vd) of drug is 76 L [5]
Chemical Identifiers
Formula
C24H30Cl2FN3O3
IUPAC Name
ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate
Canonical SMILES
CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N
InChI
InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1
InChIKey
YQZNKYXGZSVEHI-VXKWHMMOSA-N
Cross-matching ID
PubChem CID
9935639
CAS Number
380449-51-4
UNII
F70C5K4786
DrugBank ID
DB16627
TTD ID
D01HPY
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Binder [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033866)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Wickstrom M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjoberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J: Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12.
5 FDA Approved Drug Products: Pepaxto (Melphalan Flufenamide) Intravenous Injection